Pancreatic Cancer Research

ResearcherTulane UniversityActive in the last 2 years

Patrick Maisonneuve

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5309-4704; OpenAlex author ID A5013117107. Sources: OpenAlex.

Their work

Papers
34 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
176
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 7 papers · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 34

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. The projected rise of pancreatic cancer mortality in Italy: forecasts until 2035. Co-author DOI 10.1007/s13304-026-02862-w↗
  3. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. Co-author DOI 10.1016/j.clnu.2025.106573↗
  4. High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review. Co-author DOI 10.1016/j.pan.2024.11.010↗
  5. Risk of Pancreatic Cancer in Inflammatory Pancreatic Diseases. Last author DOI 10.4166/kjg.2025.019↗
  6. Re: Characteristics and Outcomes of Patients with Cystic Fibrosis and Pancreatic Cancer: A Large Database Analysis. Co-author DOI 10.1007/s12029-024-01081-z↗
  7. Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
  8. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression. Co-author DOI 10.1016/j.ejso.2020.02.016↗
  9. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  10. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  11. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  12. Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1097/cej.0000000000000572↗
  13. Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer. Co-author DOI 10.3389/fmed.2020.00495↗
  14. Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. Co-author DOI 10.3390/jcm9113720↗
  15. Epidemiology and burden of pancreatic cancer. Co-author DOI 10.1016/j.lpm.2019.02.030↗
  16. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  17. Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer. Co-author DOI 10.3390/cells9010058↗
  18. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.10.217↗
  19. Variation of the age at onset of pancreatic cancer according to tobacco smoking and family history. Co-author DOI 10.1093/ije/dyy082↗
  20. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  21. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Co-author DOI 10.1038/s41598-017-13430-z↗
  22. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Co-author DOI 10.1093/annonc/mdx019↗
  23. Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. First author DOI 10.1097/mpa.0000000000000392↗
  24. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/annonc/mdv236↗
  25. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Co-author DOI 10.1093/ije/dyu240↗
  26. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/annonc/mdu276↗
  27. Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/aje/kwt052↗
  28. Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mdt336↗
  29. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mdr120↗
  30. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Co-author DOI 10.1093/annonc/mdr541↗
  31. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mds140↗
  32. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Co-author DOI 10.1245/s10434-011-2110-8↗
  33. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1093/annonc/mdq613↗
  34. Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use? Co-author DOI 10.1093/annonc/mdr305↗

Closest collaborators

The 25 strongest of 176 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthias J. Löhr · 5 shared papers, 2020–2025 · strength 0.94
  2. Guralp Onur Ceyhan · 4 shared papers, 2020–2026 · strength 0.58
  3. Miroslav Vujasinović · 2 shared papers, 2020–2025 · strength 0.52
  4. Albert B. Lowenfels · 6 shared papers, 2012–2018 · strength 0.49
  5. Gabriele Capurso · 4 shared papers, 2017–2026 · strength 0.48
  6. Giulio Belfiori · 2 shared papers, 2024–2026 · strength 0.42
  7. Benediktas Kurlinkus · 2 shared papers, 2024–2026 · strength 0.42
  8. Asif Halimi · 2 shared papers, 2024–2026 · strength 0.42
  9. Eline S. Zwart · 2 shared papers, 2024–2026 · strength 0.42
  10. Johanna Laukkarinen · 2 shared papers, 2024–2026 · strength 0.42
  11. Reea Ahola · 2 shared papers, 2024–2026 · strength 0.42
  12. Keith John Roberts · 2 shared papers, 2024–2026 · strength 0.42
  13. Giampaolo Perri · 1 shared paper, 2026 · strength 0.39
  14. Umberto Cillo · 1 shared paper, 2026 · strength 0.39
  15. Samuele Grandi · 1 shared paper, 2026 · strength 0.39
  16. Giovanni Marchegiani · 1 shared paper, 2026 · strength 0.39
  17. Giuseppe Malleo · 3 shared papers, 2020–2026 · strength 0.38
  18. Laura Maggino · 3 shared papers, 2020–2026 · strength 0.38
  19. Roberto Salvia · 3 shared papers, 2020–2026 · strength 0.38
  20. Massimo Falconi · 3 shared papers, 2018–2026 · strength 0.38
  21. Lívia Archibugi · 3 shared papers, 2017–2026 · strength 0.37
  22. H. Bas Bueno-de-Mesquita · 11 shared papers, 2011–2020 · strength 0.35
  23. Carlo La Vecchia · 11 shared papers, 2011–2020 · strength 0.35
  24. Vasile Şandru · 2 shared papers, 2020–2026 · strength 0.34
  25. Daniel de la Iglesia · 2 shared papers, 2020–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.